The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis

Autor: Kelly Conde‐Pérez, Pablo Aja‐Macaya, Elena Buetas, Noelia Trigo‐Tasende, Mohammed Nasser‐Ali, Soraya Rumbo‐Feal, Paula Nión, Elsa Martín‐De Arribas, Lara S. Estévez, Begoña Otero‐Alén, José F. Noguera, Ángel Concha, Simón Pardiñas‐López, Miguel Carda‐Diéguez, Igor Gómez‐Randulfe, Nieves Martínez‐Lago, Susana Ladra, Luis M. A. Aparicio, Germán Bou, Álex Mira, Juan A. Vallejo, Margarita Poza

Publikováno v: Molecular Oncology, Vol 18, Iss 5, Pp 1093-1122 (2024)

The incidence of colorectal cancer (CRC) has increased worldwide, and early diagnosis is crucial to reduce mortality rates. Therefore, new noninvasive biomarkers for CRC are required. Recent studies have revealed an imbalance in the oral and gut micr

Externí odkaz: https://doaj.org/article/b1bf2e9928fb424aad8f430b52eb7a0a

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

Autor: Nieves Martínez-Lago, Teresa Calleja Chucla, Beatriz Alonso De Castro, Rafael Varela Ponte, Cristina Reboredo Rendo, Martin Igor Gomez-Randulfe Rodriguez, Sofia Silva Diaz, Begoña Graña Suarez, Juan de la Cámara Gomez, Fernando Busto Fernández, María Mateos Salvador, Margarita Reboredo Lopez

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)

Abstract We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. Patients refractory or intolerant to standard thera

Externí odkaz: https://doaj.org/article/c57ed14ff76941199d651c58407ca464

Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen

Autor: Nieves Martínez-Lago, Soledad Cameselle García, Beatriz Alonso de Castro, Martín I. Gómez-Randulfe Rodríguez, Marta Carmona Campos, Paula González Villarroel, Mercedes Salgado Fernández, Juan C. De la Cámara Gómez, Carlos Romero Reinoso, Antía Cousillas Castiñeiras, José Carlos Méndez Méndez, Yolanda Vidal Insua, Ana Fernández-Montes

Publikováno v: PLoS ONE, Vol 17, Iss 6 (2022)

Background The VELOUR study showed the benefit of FOLFIRI-Aflibercept (FA) versus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in second-line treatment. However, only 36% of the included patients were ≥65 years. Thus, we seek to eva

Externí odkaz: https://doaj.org/article/e00901a0b5b7464ca871c78422a4ada3

Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

Autor: Alberto Carmona-Bayonas, Melina Verso, Manuel Sánchez Cánovas, Jaime Rubio Pérez, Marta García de Herreros, Purificación Martínez del Prado, Isaura Fernández Pérez, Teresa Quintanar Verduguez, Berta Obispo Portero, Vanessa Pachón Olmos, David Gómez, Laura Ortega, Marta Serrano Moyano, Elena M. Brozos, Mercedes Biosca, Maite Antonio Rebollo, Lucía Teijeira Sanchez, Carolina Hernández Pérez, José David Cumplido Burón, Nieves Martínez Lago, Estefanía García Pérez, Jose Muñoz Langa, Pedro Pérez Segura, Eva Martínez de Castro, Paula Jimenez-Fonseca, Giancarlo Agnelli, Andrés Muñoz

Publikováno v: THROMBOSIS AND HAEMOSTASIS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Thrombosis and haemostasis
r-FISABIO. Repositorio Institucional de Producción Científica

BACKGROUND: Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e39ca449efdd7b5e757437bdd106d877
http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1816-8347.pdf

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

Autor: Sena Valcarcel, Javier Gallego, Paula Jimenez-Fonseca, Marc Diez, Eva Martínez de Castro, Raquel Hernandez, Virginia Arrazubi, Ana Custodio, Juana María Cano, Ana Fernández Montes, Ismael Macias, Laura Visa, Aitana Calvo, Rosario Vidal Tocino, Nieves Martínez Lago, María Luisa Limón, Mónica Granja, Mireia Gil, Paola Pimentel, Lola Macia-Rivas, Carolina Hernández Pérez, Montserrat Mangas, Alfonso Martín Carnicero, Paula Cerdà, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Mª Dolores Mediano Rambla, Marta Martin Richard, Alberto Carmona-Bayonas

Publikováno v: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
J CANCER RES CLIN
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante

PURPOSE: This study aimed to compare ramucirumab-paclitaxel versus chemotherapy in second-line (2L) advanced gastroesophageal cancer (aGEC) based on HER2 status and analyze prognostic factors. METHODS: The study includes patients from the AGAMENON-SE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadd4716e4d425b3624cc9d2a98d8eec
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13995